Jean Dudler
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
Riek M, Scherer A, Möller B, Ciurea A, Von Mühlenen I, Gabay C, Kyburz D, Brulhart L, von Kempis J, Mueller R, Hasler P, Strahm T, von Känel S, Zufferey P, Dudler J, Finckh A. Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. Sci Rep 2023; 13:17776.
18.10.2023Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
18.10.2023Sci Rep 2023; 13:17776
Riek Myriam, Scherer Almut, Möller Burkhard, Ciurea Adrian, Von Mühlenen Ines, Gabay Cem, Kyburz Diego, Brulhart Laure, von Kempis Johannes, Mueller Ruediger B, Hasler Paul, Strahm Tanja, von Känel Sabine, Zufferey Pascal, Dudler Jean, Finckh Axel
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
Amstad A, Papagiannoulis E, Scherer A, Rubbert-Roth A, Finckh A, Mueller R, Dudler J, Möller B, Villiger P, Schulz M, Kyburz D. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. Rheumatology (Oxford) 2022; 62:89-97.
23.12.2022Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
23.12.2022Rheumatology (Oxford) 2022; 62:89-97
Amstad Andrea, Papagiannoulis Eleftherios, Scherer Almut, Rubbert-Roth Andrea, Finckh Axel, Mueller Ruediger, Dudler Jean, Möller Burkhard, Villiger Peter M, Schulz Martin, Kyburz Diego
Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis
Alpizar-Rodriguez D, Gabay C, Courvoisier D, Lamacchia C, Mahler M, Roux-Lombard P, Von Mühlenen I, Walker U, Kyburz D, Zufferey P, Ciurea A, Dudler J, Möller B, Müller R, Finckh A. Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. Rheumatology (Oxford) 2017; 56:1579-1585.
01.09.2017Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis
01.09.2017Rheumatology (Oxford) 2017; 56:1579-1585
Alpizar-Rodriguez Deshiré, Gabay Cem, Courvoisier Delphine S, Lamacchia Céline, Mahler Michael, Roux-Lombard Pascale, Von Mühlenen Ines, Walker Ulrich A, Kyburz Diego, Zufferey Pascal, Ciurea Adrian, Dudler Jean, Möller Burkhard, Müller Rüdiger, Finckh Axel
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis
Alpizar-Rodriguez D, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Nissen M, Courvoisier D, Gabay C, Mahler M, Zufferey P, Brulhart L, Müller R, Möller B, Dudler J, Ciurea A, Walker U, Von Mühlenen I, Kyburz D, Finckh A. The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis. Clin Rheumatol 2017
21.01.2017The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis
21.01.2017Clin Rheumatol 2017
Alpizar-Rodriguez D, Bas Sylvette, Gascon Danielle, Lamacchia Céline, Roux-Lombard Pascale, Lauper Kim, Nissen Michael J, Courvoisier Delphine S, Gabay Cem, Mahler Michael, Zufferey Pascal, Brulhart Laure, Müller Rüdiger, Möller Burkhard, Dudler Jean, Ciurea Adrian, Walker Ulrich A, Von Mühlenen Ines, Kyburz Diego, Finckh Axel
Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
Müller R, Gengenbacher M, Richter S, Dudler J, Möller B, von Kempis J. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). Arthritis Res Ther 2016; 18:88.
14.04.2016Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
14.04.2016Arthritis Res Ther 2016; 18:88
Müller Rüdiger, Gengenbacher Michael, Richter Symi, Dudler Jean, Möller Burkhard, von Kempis Johannes
The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologists
Boehncke W, Yawalkar N, Villiger P, Navarini A, Möller B, Michel B, Laffitte E, Kyburz D, Häusermann P, Hasler P, Hasler F, Dudler J, Conrad C, Anliker M, Gabay C. The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologists. Dermatology (Basel) 2015; 230:75-81.
06.01.2015The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologists
06.01.2015Dermatology (Basel) 2015; 230:75-81
Boehncke Wolf-Henning, Yawalkar Nikhil, Villiger Peter M, Navarini Alexander A, Möller Burkhard, Michel Beat A, Laffitte Emmanuel, Kyburz Diego, Häusermann Peter, Hasler Paul, Hasler Fritz, Dudler Jean, Conrad Curdin, Anliker Mark, Gabay Cem
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort
Ciurea A, Weber U, Boonen A, Dougados M, van der Heijde D, Michel B, Nissen M, Müller R, Weiss B, Tamborrini G, Rufibach K, Stekhoven D, Kissling R, Beyeler B, Dudler J, Bernhard J, Exer P, Scherer A, Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum 2013; 65:3096-106.
01.12.2013Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort
01.12.2013Arthritis Rheum 2013; 65:3096-106
Ciurea Adrian, Weber Ulrich, Boonen Annelies, Dougados Maxime, van der Heijde Désirée, Michel Beat A, Nissen Michael J, Müller Rüdiger, Weiss Bettina, Tamborrini Giorgio, Rufibach Kaspar, Stekhoven Daniel, Kissling Rudolf, Beyeler Brigitte, Dudler Jean, Bernhard Jürg, Exer Pascale, Scherer Almut, Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis
Use of abatacept in rheumatoid arthritis
von Kempis J, Dudler J, Hasler P, Kyburz D, Tyndall A, Zufferey P, Villiger P. Use of abatacept in rheumatoid arthritis. Swiss Med Wkly 2012; 142:w13581.
11.05.2012Use of abatacept in rheumatoid arthritis
11.05.2012Swiss Med Wkly 2012; 142:w13581
von Kempis Johannes, Dudler Jean, Hasler Paul, Kyburz Diego, Tyndall Alan, Zufferey Pascal, Villiger Peter M
Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion
Walker U, Courvoisier D, Dudler J, Aeberli D, von Kempis J, Scherer A, Finckh A, Swiss Clinical Quality Management Programme in Rheumatic Diseases. Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion. Rheumatology (Oxford) 2010; 50:243-4.
17.08.2010Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion
17.08.2010Rheumatology (Oxford) 2010; 50:243-4
Walker Ulrich A, Courvoisier Delphine S, Dudler Jean, Aeberli Daniel, von Kempis Johannes, Scherer Almut, Finckh Axel, Swiss Clinical Quality Management Programme in Rheumatic Diseases